Drug intelligence / Profile preview

CMV-ALT + CMV-DCs

Development stage: Preclinical
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous, Intradermal, Subcutaneous

Overview

CMV-ALT + CMV-DCs appears to be a combination immunotherapy approach using autologous T cells specific for cytomegalovirus (CMV) antigens combined with dendritic cells loaded with CMV antigens. This therapy is being investigated for glioblastoma multiforme (GBM) treatment. The approach involves isolating dendritic cells from patients, electroporating them with CMV pp65 mRNA, and administering them along with CMV-specific T cells.

Targets

CMV-TCR (Cytomegalovirus-specific T-cell receptor)

Beyond the preview

Go deeper on CMV-ALT + CMV-DCs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMV-ALT + CMV-DCs.

Explore the full profile